Title : The potential application of recombinant swinepox virus expressing protective antigens of ASFV
Abstract:
African swine fever (ASF) is caused by African swine fever virus (ASFV). The mortality rate of domestic pigs and wild boars is as high as 100%, and they can also infect pigs and ticks as carriers and infection hosts. So far there is no commercialized ASF vaccine. The prevention and control of ASF only relies on biosecurity, which is costly. Therefore, it is imperative to develop an effective vaccine for the prevention and control of ASFV. As a vaccine vector, Swinepox virus (SPV) has strict host specificity and good safety. In this study, the recombinant SPV vaccine expressing ASFV protective antigen p72 and truncated p54 was constructed. The expression of the inserted gene fragments were identified by IFA and Western Blot. The titer of recombinant virus was determined by calculating the copy number. The results of animal experiment showed that the level of the p72-specific antibody and the p54-specific antibody of the rSPV-p72-p54 vaccinated piglets were significantly higher at all time points post-vaccination than those of the subunit vaccine of ASFV vaccinated piglets (P < 0.05), wtSPV (P < 0.001) or mock treated piglets (P < 0.001). The IL-4 and IFN-γ in the rSPV-p72-p54 group were significantly higher than the other three groups at all post-infection time points. These results suggest the possibility of using recombinant swinepox virus rSPV-p72-p54 as a promising vaccine to prevent ASFV infection.
Audience Take Away:
- The recombinant swinepox virus (rSPV) is a potential vaccine vector.
- Multiple exogenous protective antigens can be expressed simultaneously in rSPV vector vaccine.
- The rSPV vector vaccines elicit potent Th1-type and Th2-type cytokine responses in animals.
